33286-30-5
Chemical Structure
Carboxyatractyloside dipotassium
Synonym(s): Gummiferin dipotassium
- CAS No.: 33286-30-5
- Formula:C31H44K2O18S2
- Molecular Weight:847.00
IUPAC Name: potassium (2R,3R,4R,5R,6R)-6-(((2S,4aS,6aR,7S,9R,11aS,11bS)-4,4-dicarboxy-7-hydroxy-11b-methyl-8-methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalen-2-yl)oxy)-2-(hydroxymethyl)-5-((3-methylbutanoyl)oxy)tetrahydro-2H-pyran-3,4-diyl bis(sulfate)
InChIKey: FPJGZZYAZUKPAD-WWJHHVHBSA-L
SMILES: C=C([C@H](CC1)C2)[C@H](O)[C@@]32CC[C@]4([H])C(C(O)=O)(C(O)=O)C[C@@H](O[C@H]5[C@@H]([C@H]([C@@H]([C@@H](CO)O5)OS(=O)(O[K])=O)OS(=O)(O[K])=O)OC(CC(C)C)=O)C[C@@]4(C)[C@@]31[H]
Biological Activity: Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carboxyatractyloside dipotassium | 99.57% | Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carboxyatractyloside dipotassium (Standard) | ≥98% | Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ri M, et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012 Jul;2(7):e79. [Content Brief]
- [2]. Belosludtseva NV, et al. ANT-Mediated Inhibition of the Permeability Transition Pore Alleviates Palmitate-Induced Mitochondrial Dysfunction and Lipotoxicity. Biomolecules. 2024 Sep 15;14(9):1159. [Content Brief]
- [3]. García N, et al. Cyclosporin A is unable to inhibit carboxyatractyloside-induced permeability transition in aged mitochondria. Comp Biochem Physiol C Toxicol Pharmacol. 2009 Apr;149(3):374-81. [Content Brief]
- [4]. Luciani S, et al. Effects of carboxyatractyloside a structural analogue of atractyloside on mitochondrial oxidative phosphorylation. Life Sci II. 1971 Sep 8;10(17):961-8. [Content Brief]
- [5]. Hatch RC, et al. Toxicologic study of carboxyatractyloside (active principle in cocklebur--Xanthium strumarium) in rats treated with enzyme inducers and inhibitors and glutathione precursor and depletor. Am J Vet Res. 1982 Jan;43(1):111-6. [Content Brief]
- [6]. Pebay-Peyroula E, et al. Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. Nature. 2003 Nov 6;426(6962):39-44.
